DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation
The inflammatory cytokine interleukin-6 (IL-6) is critical for the expression of octamer-binding transcription factor 4 (OCT4), which is highly associated with early tumor recurrence and poor prognosis of hepatocellular carcinomas (HCC). DNA methyltransferase (DNMT) family is closely linked with OCT...
Saved in:
| Published in | Journal of experimental & clinical cancer research Vol. 38; no. 1; pp. 474 - 18 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
26.11.2019
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1756-9966 0392-9078 1756-9966 |
| DOI | 10.1186/s13046-019-1442-2 |
Cover
Loading…
| Abstract | The inflammatory cytokine interleukin-6 (IL-6) is critical for the expression of octamer-binding transcription factor 4 (OCT4), which is highly associated with early tumor recurrence and poor prognosis of hepatocellular carcinomas (HCC). DNA methyltransferase (DNMT) family is closely linked with OCT4 expression and drug resistance. However, the underlying mechanism regarding the interplay between DNMTs and IL-6-induced OCT4 expression and the sorafenib resistance of HCC remains largely unclear.
HCC tissue samples were used to examine the association between DNMTs/OCT4 expression levels and clinical prognosis. Serum levels of IL-6 were detected using ELISA assays (n = 144). Gain- and loss-of-function experiments were performed in cell lines and mouse xenograft models to determine the underlying mechanism in vitro and in vivo.
We demonstrate that levels of DNA methyltransferase 3 beta (DNMT3b) are significantly correlated with the OCT4 levels in HCC tissues (n = 144), and the OCT4 expression levels are positively associated with the serum IL-6 levels. Higher levels of IL-6, DNMT3b, or OCT4 predicted early HCC recurrence and poor prognosis. We show that IL-6/STAT3 activation increases DNMT3b/1 and OCT4 in HCC. Activated phospho-STAT3 (STAT-Y640F) significantly increased DNMT3b/OCT4, while dominant negative phospho-STAT3 (STAT-Y705F) was suppressive. Inhibiting DNMT3b with RNA interference or nanaomycin A (a selective DNMT3b inhibitor) effectively suppressed the IL-6 or STAT-Y640F-induced increase of DNMT3b-OCT4 and ALDH activity in vitro and in vivo. The fact that OCT4 regulates the DNMT1 expressions were further demonstrated either by OCT4 forced expression or DNMT1 silence. Additionally, the DNMT3b silencing reduced the OCT4 expression in sorafenib-resistant Hep3B cells with or without IL-6 treatment. Notably, targeting DNMT3b with nanaomycin A significantly increased the cell sensitivity to sorafenib, with a synergistic combination index (CI) in sorafenib-resistant Hep3B cells.
The DNMT3b plays a critical role in the IL-6-mediated OCT4 expression and the drug sensitivity of sorafenib-resistant HCC. The p-STAT3 activation increases the DNMT3b/OCT4 which confers the tumor early recurrence and poor prognosis of HCC patients. Findings from this study highlight the significance of IL-6-DNMT3b-mediated OCT4 expressions in future therapeutic target for patients expressing cancer stemness-related properties or sorafenib resistance in HCC. |
|---|---|
| AbstractList | Abstract Background The inflammatory cytokine interleukin-6 (IL-6) is critical for the expression of octamer-binding transcription factor 4 (OCT4), which is highly associated with early tumor recurrence and poor prognosis of hepatocellular carcinomas (HCC). DNA methyltransferase (DNMT) family is closely linked with OCT4 expression and drug resistance. However, the underlying mechanism regarding the interplay between DNMTs and IL-6-induced OCT4 expression and the sorafenib resistance of HCC remains largely unclear. Methods HCC tissue samples were used to examine the association between DNMTs/OCT4 expression levels and clinical prognosis. Serum levels of IL-6 were detected using ELISA assays (n = 144). Gain- and loss-of-function experiments were performed in cell lines and mouse xenograft models to determine the underlying mechanism in vitro and in vivo. Results We demonstrate that levels of DNA methyltransferase 3 beta (DNMT3b) are significantly correlated with the OCT4 levels in HCC tissues (n = 144), and the OCT4 expression levels are positively associated with the serum IL-6 levels. Higher levels of IL-6, DNMT3b, or OCT4 predicted early HCC recurrence and poor prognosis. We show that IL-6/STAT3 activation increases DNMT3b/1 and OCT4 in HCC. Activated phospho-STAT3 (STAT-Y640F) significantly increased DNMT3b/OCT4, while dominant negative phospho-STAT3 (STAT-Y705F) was suppressive. Inhibiting DNMT3b with RNA interference or nanaomycin A (a selective DNMT3b inhibitor) effectively suppressed the IL-6 or STAT-Y640F-induced increase of DNMT3b-OCT4 and ALDH activity in vitro and in vivo. The fact that OCT4 regulates the DNMT1 expressions were further demonstrated either by OCT4 forced expression or DNMT1 silence. Additionally, the DNMT3b silencing reduced the OCT4 expression in sorafenib-resistant Hep3B cells with or without IL-6 treatment. Notably, targeting DNMT3b with nanaomycin A significantly increased the cell sensitivity to sorafenib, with a synergistic combination index (CI) in sorafenib-resistant Hep3B cells. Conclusions The DNMT3b plays a critical role in the IL-6-mediated OCT4 expression and the drug sensitivity of sorafenib-resistant HCC. The p-STAT3 activation increases the DNMT3b/OCT4 which confers the tumor early recurrence and poor prognosis of HCC patients. Findings from this study highlight the significance of IL-6-DNMT3b–mediated OCT4 expressions in future therapeutic target for patients expressing cancer stemness-related properties or sorafenib resistance in HCC. The inflammatory cytokine interleukin-6 (IL-6) is critical for the expression of octamer-binding transcription factor 4 (OCT4), which is highly associated with early tumor recurrence and poor prognosis of hepatocellular carcinomas (HCC). DNA methyltransferase (DNMT) family is closely linked with OCT4 expression and drug resistance. However, the underlying mechanism regarding the interplay between DNMTs and IL-6-induced OCT4 expression and the sorafenib resistance of HCC remains largely unclear.BACKGROUNDThe inflammatory cytokine interleukin-6 (IL-6) is critical for the expression of octamer-binding transcription factor 4 (OCT4), which is highly associated with early tumor recurrence and poor prognosis of hepatocellular carcinomas (HCC). DNA methyltransferase (DNMT) family is closely linked with OCT4 expression and drug resistance. However, the underlying mechanism regarding the interplay between DNMTs and IL-6-induced OCT4 expression and the sorafenib resistance of HCC remains largely unclear.HCC tissue samples were used to examine the association between DNMTs/OCT4 expression levels and clinical prognosis. Serum levels of IL-6 were detected using ELISA assays (n = 144). Gain- and loss-of-function experiments were performed in cell lines and mouse xenograft models to determine the underlying mechanism in vitro and in vivo.METHODSHCC tissue samples were used to examine the association between DNMTs/OCT4 expression levels and clinical prognosis. Serum levels of IL-6 were detected using ELISA assays (n = 144). Gain- and loss-of-function experiments were performed in cell lines and mouse xenograft models to determine the underlying mechanism in vitro and in vivo.We demonstrate that levels of DNA methyltransferase 3 beta (DNMT3b) are significantly correlated with the OCT4 levels in HCC tissues (n = 144), and the OCT4 expression levels are positively associated with the serum IL-6 levels. Higher levels of IL-6, DNMT3b, or OCT4 predicted early HCC recurrence and poor prognosis. We show that IL-6/STAT3 activation increases DNMT3b/1 and OCT4 in HCC. Activated phospho-STAT3 (STAT-Y640F) significantly increased DNMT3b/OCT4, while dominant negative phospho-STAT3 (STAT-Y705F) was suppressive. Inhibiting DNMT3b with RNA interference or nanaomycin A (a selective DNMT3b inhibitor) effectively suppressed the IL-6 or STAT-Y640F-induced increase of DNMT3b-OCT4 and ALDH activity in vitro and in vivo. The fact that OCT4 regulates the DNMT1 expressions were further demonstrated either by OCT4 forced expression or DNMT1 silence. Additionally, the DNMT3b silencing reduced the OCT4 expression in sorafenib-resistant Hep3B cells with or without IL-6 treatment. Notably, targeting DNMT3b with nanaomycin A significantly increased the cell sensitivity to sorafenib, with a synergistic combination index (CI) in sorafenib-resistant Hep3B cells.RESULTSWe demonstrate that levels of DNA methyltransferase 3 beta (DNMT3b) are significantly correlated with the OCT4 levels in HCC tissues (n = 144), and the OCT4 expression levels are positively associated with the serum IL-6 levels. Higher levels of IL-6, DNMT3b, or OCT4 predicted early HCC recurrence and poor prognosis. We show that IL-6/STAT3 activation increases DNMT3b/1 and OCT4 in HCC. Activated phospho-STAT3 (STAT-Y640F) significantly increased DNMT3b/OCT4, while dominant negative phospho-STAT3 (STAT-Y705F) was suppressive. Inhibiting DNMT3b with RNA interference or nanaomycin A (a selective DNMT3b inhibitor) effectively suppressed the IL-6 or STAT-Y640F-induced increase of DNMT3b-OCT4 and ALDH activity in vitro and in vivo. The fact that OCT4 regulates the DNMT1 expressions were further demonstrated either by OCT4 forced expression or DNMT1 silence. Additionally, the DNMT3b silencing reduced the OCT4 expression in sorafenib-resistant Hep3B cells with or without IL-6 treatment. Notably, targeting DNMT3b with nanaomycin A significantly increased the cell sensitivity to sorafenib, with a synergistic combination index (CI) in sorafenib-resistant Hep3B cells.The DNMT3b plays a critical role in the IL-6-mediated OCT4 expression and the drug sensitivity of sorafenib-resistant HCC. The p-STAT3 activation increases the DNMT3b/OCT4 which confers the tumor early recurrence and poor prognosis of HCC patients. Findings from this study highlight the significance of IL-6-DNMT3b-mediated OCT4 expressions in future therapeutic target for patients expressing cancer stemness-related properties or sorafenib resistance in HCC.CONCLUSIONSThe DNMT3b plays a critical role in the IL-6-mediated OCT4 expression and the drug sensitivity of sorafenib-resistant HCC. The p-STAT3 activation increases the DNMT3b/OCT4 which confers the tumor early recurrence and poor prognosis of HCC patients. Findings from this study highlight the significance of IL-6-DNMT3b-mediated OCT4 expressions in future therapeutic target for patients expressing cancer stemness-related properties or sorafenib resistance in HCC. Background The inflammatory cytokine interleukin-6 (IL-6) is critical for the expression of octamer-binding transcription factor 4 (OCT4), which is highly associated with early tumor recurrence and poor prognosis of hepatocellular carcinomas (HCC). DNA methyltransferase (DNMT) family is closely linked with OCT4 expression and drug resistance. However, the underlying mechanism regarding the interplay between DNMTs and IL-6-induced OCT4 expression and the sorafenib resistance of HCC remains largely unclear. Methods HCC tissue samples were used to examine the association between DNMTs/OCT4 expression levels and clinical prognosis. Serum levels of IL-6 were detected using ELISA assays (n = 144). Gain- and loss-of-function experiments were performed in cell lines and mouse xenograft models to determine the underlying mechanism in vitro and in vivo. Results We demonstrate that levels of DNA methyltransferase 3 beta (DNMT3b) are significantly correlated with the OCT4 levels in HCC tissues (n = 144), and the OCT4 expression levels are positively associated with the serum IL-6 levels. Higher levels of IL-6, DNMT3b, or OCT4 predicted early HCC recurrence and poor prognosis. We show that IL-6/STAT3 activation increases DNMT3b/1 and OCT4 in HCC. Activated phospho-STAT3 (STAT-Y640F) significantly increased DNMT3b/OCT4, while dominant negative phospho-STAT3 (STAT-Y705F) was suppressive. Inhibiting DNMT3b with RNA interference or nanaomycin A (a selective DNMT3b inhibitor) effectively suppressed the IL-6 or STAT-Y640F-induced increase of DNMT3b-OCT4 and ALDH activity in vitro and in vivo. The fact that OCT4 regulates the DNMT1 expressions were further demonstrated either by OCT4 forced expression or DNMT1 silence. Additionally, the DNMT3b silencing reduced the OCT4 expression in sorafenib-resistant Hep3B cells with or without IL-6 treatment. Notably, targeting DNMT3b with nanaomycin A significantly increased the cell sensitivity to sorafenib, with a synergistic combination index (CI) in sorafenib-resistant Hep3B cells. Conclusions The DNMT3b plays a critical role in the IL-6-mediated OCT4 expression and the drug sensitivity of sorafenib-resistant HCC. The p-STAT3 activation increases the DNMT3b/OCT4 which confers the tumor early recurrence and poor prognosis of HCC patients. Findings from this study highlight the significance of IL-6-DNMT3b–mediated OCT4 expressions in future therapeutic target for patients expressing cancer stemness-related properties or sorafenib resistance in HCC. Background The inflammatory cytokine interleukin-6 (IL-6) is critical for the expression of octamer-binding transcription factor 4 (OCT4), which is highly associated with early tumor recurrence and poor prognosis of hepatocellular carcinomas (HCC). DNA methyltransferase (DNMT) family is closely linked with OCT4 expression and drug resistance. However, the underlying mechanism regarding the interplay between DNMTs and IL-6-induced OCT4 expression and the sorafenib resistance of HCC remains largely unclear. Methods HCC tissue samples were used to examine the association between DNMTs/OCT4 expression levels and clinical prognosis. Serum levels of IL-6 were detected using ELISA assays (n = 144). Gain- and loss-of-function experiments were performed in cell lines and mouse xenograft models to determine the underlying mechanism in vitro and in vivo. Results We demonstrate that levels of DNA methyltransferase 3 beta (DNMT3b) are significantly correlated with the OCT4 levels in HCC tissues (n = 144), and the OCT4 expression levels are positively associated with the serum IL-6 levels. Higher levels of IL-6, DNMT3b, or OCT4 predicted early HCC recurrence and poor prognosis. We show that IL-6/STAT3 activation increases DNMT3b/1 and OCT4 in HCC. Activated phospho-STAT3 (STAT-Y640F) significantly increased DNMT3b/OCT4, while dominant negative phospho-STAT3 (STAT-Y705F) was suppressive. Inhibiting DNMT3b with RNA interference or nanaomycin A (a selective DNMT3b inhibitor) effectively suppressed the IL-6 or STAT-Y640F-induced increase of DNMT3b-OCT4 and ALDH activity in vitro and in vivo. The fact that OCT4 regulates the DNMT1 expressions were further demonstrated either by OCT4 forced expression or DNMT1 silence. Additionally, the DNMT3b silencing reduced the OCT4 expression in sorafenib-resistant Hep3B cells with or without IL-6 treatment. Notably, targeting DNMT3b with nanaomycin A significantly increased the cell sensitivity to sorafenib, with a synergistic combination index (CI) in sorafenib-resistant Hep3B cells. Conclusions The DNMT3b plays a critical role in the IL-6-mediated OCT4 expression and the drug sensitivity of sorafenib-resistant HCC. The p-STAT3 activation increases the DNMT3b/OCT4 which confers the tumor early recurrence and poor prognosis of HCC patients. Findings from this study highlight the significance of IL-6-DNMT3b-mediated OCT4 expressions in future therapeutic target for patients expressing cancer stemness-related properties or sorafenib resistance in HCC. Keywords: Interleukin-6, Phospho-STAT3, OCT4, DNMT3b, Drug resistance, Hepatocellular carcinoma The inflammatory cytokine interleukin-6 (IL-6) is critical for the expression of octamer-binding transcription factor 4 (OCT4), which is highly associated with early tumor recurrence and poor prognosis of hepatocellular carcinomas (HCC). DNA methyltransferase (DNMT) family is closely linked with OCT4 expression and drug resistance. However, the underlying mechanism regarding the interplay between DNMTs and IL-6-induced OCT4 expression and the sorafenib resistance of HCC remains largely unclear. HCC tissue samples were used to examine the association between DNMTs/OCT4 expression levels and clinical prognosis. Serum levels of IL-6 were detected using ELISA assays (n = 144). Gain- and loss-of-function experiments were performed in cell lines and mouse xenograft models to determine the underlying mechanism in vitro and in vivo. We demonstrate that levels of DNA methyltransferase 3 beta (DNMT3b) are significantly correlated with the OCT4 levels in HCC tissues (n = 144), and the OCT4 expression levels are positively associated with the serum IL-6 levels. Higher levels of IL-6, DNMT3b, or OCT4 predicted early HCC recurrence and poor prognosis. We show that IL-6/STAT3 activation increases DNMT3b/1 and OCT4 in HCC. Activated phospho-STAT3 (STAT-Y640F) significantly increased DNMT3b/OCT4, while dominant negative phospho-STAT3 (STAT-Y705F) was suppressive. Inhibiting DNMT3b with RNA interference or nanaomycin A (a selective DNMT3b inhibitor) effectively suppressed the IL-6 or STAT-Y640F-induced increase of DNMT3b-OCT4 and ALDH activity in vitro and in vivo. The fact that OCT4 regulates the DNMT1 expressions were further demonstrated either by OCT4 forced expression or DNMT1 silence. Additionally, the DNMT3b silencing reduced the OCT4 expression in sorafenib-resistant Hep3B cells with or without IL-6 treatment. Notably, targeting DNMT3b with nanaomycin A significantly increased the cell sensitivity to sorafenib, with a synergistic combination index (CI) in sorafenib-resistant Hep3B cells. The DNMT3b plays a critical role in the IL-6-mediated OCT4 expression and the drug sensitivity of sorafenib-resistant HCC. The p-STAT3 activation increases the DNMT3b/OCT4 which confers the tumor early recurrence and poor prognosis of HCC patients. Findings from this study highlight the significance of IL-6-DNMT3b-mediated OCT4 expressions in future therapeutic target for patients expressing cancer stemness-related properties or sorafenib resistance in HCC. The inflammatory cytokine interleukin-6 (IL-6) is critical for the expression of octamer-binding transcription factor 4 (OCT4), which is highly associated with early tumor recurrence and poor prognosis of hepatocellular carcinomas (HCC). DNA methyltransferase (DNMT) family is closely linked with OCT4 expression and drug resistance. However, the underlying mechanism regarding the interplay between DNMTs and IL-6-induced OCT4 expression and the sorafenib resistance of HCC remains largely unclear. HCC tissue samples were used to examine the association between DNMTs/OCT4 expression levels and clinical prognosis. Serum levels of IL-6 were detected using ELISA assays (n = 144). Gain- and loss-of-function experiments were performed in cell lines and mouse xenograft models to determine the underlying mechanism in vitro and in vivo. We demonstrate that levels of DNA methyltransferase 3 beta (DNMT3b) are significantly correlated with the OCT4 levels in HCC tissues (n = 144), and the OCT4 expression levels are positively associated with the serum IL-6 levels. Higher levels of IL-6, DNMT3b, or OCT4 predicted early HCC recurrence and poor prognosis. We show that IL-6/STAT3 activation increases DNMT3b/1 and OCT4 in HCC. Activated phospho-STAT3 (STAT-Y640F) significantly increased DNMT3b/OCT4, while dominant negative phospho-STAT3 (STAT-Y705F) was suppressive. Inhibiting DNMT3b with RNA interference or nanaomycin A (a selective DNMT3b inhibitor) effectively suppressed the IL-6 or STAT-Y640F-induced increase of DNMT3b-OCT4 and ALDH activity in vitro and in vivo. The fact that OCT4 regulates the DNMT1 expressions were further demonstrated either by OCT4 forced expression or DNMT1 silence. Additionally, the DNMT3b silencing reduced the OCT4 expression in sorafenib-resistant Hep3B cells with or without IL-6 treatment. Notably, targeting DNMT3b with nanaomycin A significantly increased the cell sensitivity to sorafenib, with a synergistic combination index (CI) in sorafenib-resistant Hep3B cells. The DNMT3b plays a critical role in the IL-6-mediated OCT4 expression and the drug sensitivity of sorafenib-resistant HCC. The p-STAT3 activation increases the DNMT3b/OCT4 which confers the tumor early recurrence and poor prognosis of HCC patients. Findings from this study highlight the significance of IL-6-DNMT3b-mediated OCT4 expressions in future therapeutic target for patients expressing cancer stemness-related properties or sorafenib resistance in HCC. |
| ArticleNumber | 474 |
| Audience | Academic |
| Author | Lee, Kam-Fai Chang, Te-Sheng Kuo, Yung-Che Su, Yu-Ting Chi, Ching-Chi Lan, Pei-Chi Yang, Muh-Hwa Huang, Yen-Hua Wu, Yu-Chih Lai, Ssu-Chuan |
| Author_xml | – sequence: 1 givenname: Ssu-Chuan surname: Lai fullname: Lai, Ssu-Chuan – sequence: 2 givenname: Yu-Ting surname: Su fullname: Su, Yu-Ting – sequence: 3 givenname: Ching-Chi surname: Chi fullname: Chi, Ching-Chi – sequence: 4 givenname: Yung-Che surname: Kuo fullname: Kuo, Yung-Che – sequence: 5 givenname: Kam-Fai surname: Lee fullname: Lee, Kam-Fai – sequence: 6 givenname: Yu-Chih surname: Wu fullname: Wu, Yu-Chih – sequence: 7 givenname: Pei-Chi surname: Lan fullname: Lan, Pei-Chi – sequence: 8 givenname: Muh-Hwa surname: Yang fullname: Yang, Muh-Hwa – sequence: 9 givenname: Te-Sheng surname: Chang fullname: Chang, Te-Sheng – sequence: 10 givenname: Yen-Hua orcidid: 0000-0001-6020-9998 surname: Huang fullname: Huang, Yen-Hua |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31771617$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks1u1DAUhSNURNuBB2CDLCEhNml97cRJNkij4W-kgS4Y1pbj2IlHGTvYCYIdj47TKWWmQiiLxNffPY7PPZfJmXVWJclzwFcAJbsOQHHGUgxVCllGUvIouYAiZ2lVMXZ29H2eXIaww5hBBdWT5JxCUQCD4iL59fbzpy2tr29W2wypH4NXIRhnkXRWKx9QcF5oZU2N4o4Jo7BSIWEbNDjn0eBda12sI6dRpwYxOqn6fuqFR1J4aazbCzR23k1th9ablF1_2S63NIq1ERrjSU-Tx1r0QT27ey-Sr-_fbVcf083Nh_VquUkly4sxbUAXmDKJ46osmSICl5ARaChRBKRsmgyLHNc504xmuMaM4SKrqgrnDS10SRfJ-qDbOLHjgzd74X9yJwy_LTjfcuFHI3vFS9Ba5VVZA2kyhoUgdVHVUgkgsiH5rPXmoDVM9V41UtnRi_5E9HTHmo637jtnZVEyxqLA6zsB775NKox8b8LsnLDKTYETOg8qzwBH9OUDdOcmb6NVkSIljX4A_Uu1Il7AWO3iuXIW5cvZCEwxhkhd_YOKT6P2Jk5caRPrJw2vjho6JfqxC66f5sGFU_DFsSP3VvwJWgTgAEjvQvBK3yOA-Rxmfggzj2Hmc5jj7RZJ8aBHmvE2NPG3Tf-fzt8Ly_WJ |
| CitedBy_id | crossref_primary_10_1042_EBC20220001 crossref_primary_10_1007_s12032_022_01943_1 crossref_primary_10_2478_fzm_2022_0016 crossref_primary_10_3390_cancers13194876 crossref_primary_10_3390_ijms241713603 crossref_primary_10_3390_biomedicines12010045 crossref_primary_10_1016_j_canlet_2020_05_035 crossref_primary_10_2147_JHC_S469449 crossref_primary_10_3389_fonc_2020_592891 crossref_primary_10_3390_jpm13010005 crossref_primary_10_3389_fcell_2020_625943 crossref_primary_10_18632_aging_204333 crossref_primary_10_3390_cancers15235600 crossref_primary_10_7759_cureus_50703 crossref_primary_10_3389_fonc_2022_1015527 crossref_primary_10_3390_curroncol29080434 crossref_primary_10_1038_s41401_024_01261_4 crossref_primary_10_1002_mog2_59 crossref_primary_10_1038_s41419_020_02934_8 crossref_primary_10_1097_j_pain_0000000000003536 crossref_primary_10_3389_fphar_2022_991052 crossref_primary_10_2174_1381612828666220818150959 crossref_primary_10_3389_fonc_2023_1192472 crossref_primary_10_3390_cancers15143740 crossref_primary_10_1360_SSV_2023_0139 crossref_primary_10_1016_j_prmcm_2022_100057 crossref_primary_10_1097_MD_0000000000022804 crossref_primary_10_1097_MD_0000000000037394 crossref_primary_10_1002_mco2_173 crossref_primary_10_1007_s12032_024_02359_9 crossref_primary_10_1055_s_0043_1776127 crossref_primary_10_3390_ijms222413627 crossref_primary_10_1007_s00018_023_04742_7 crossref_primary_10_3389_fonc_2023_1288909 crossref_primary_10_1007_s12032_025_02675_8 crossref_primary_10_3390_cells9061450 crossref_primary_10_5582_bst_2022_01109 crossref_primary_10_1038_s41420_024_02146_5 crossref_primary_10_1038_s41392_023_01480_x crossref_primary_10_1016_j_omtn_2022_08_013 crossref_primary_10_1038_s41421_023_00528_0 crossref_primary_10_1038_s41392_023_01341_7 crossref_primary_10_1186_s13046_019_1518_z crossref_primary_10_1002_2211_5463_13734 crossref_primary_10_3390_biom12030417 crossref_primary_10_1016_j_canlet_2025_217472 crossref_primary_10_1016_j_jri_2023_104133 crossref_primary_10_3390_cancers13153812 crossref_primary_10_3389_fmmed_2022_1011882 crossref_primary_10_3390_ijms23031667 crossref_primary_10_3390_molecules27196236 crossref_primary_10_3389_fonc_2022_988956 crossref_primary_10_1002_advs_202405997 crossref_primary_10_1158_0008_5472_CAN_20_2480 crossref_primary_10_2147_JHC_S312604 crossref_primary_10_3390_cancers12082296 crossref_primary_10_1007_s13402_022_00717_1 crossref_primary_10_1016_j_cca_2020_01_014 crossref_primary_10_3389_fgene_2020_00917 crossref_primary_10_3390_ijms22041931 crossref_primary_10_1016_j_intimp_2023_110043 crossref_primary_10_1177_1533033820977524 crossref_primary_10_1097_CM9_0000000000003439 crossref_primary_10_1080_14737159_2021_1987217 crossref_primary_10_1016_j_neo_2022_100788 crossref_primary_10_1093_toxres_tfab018 crossref_primary_10_1186_s12943_025_02265_2 crossref_primary_10_1186_s40164_024_00527_1 crossref_primary_10_1016_j_heliyon_2024_e32366 crossref_primary_10_3389_fcell_2021_645381 crossref_primary_10_3389_fonc_2021_719896 crossref_primary_10_3389_fmed_2024_1437226 crossref_primary_10_1016_j_biomaterials_2025_123175 crossref_primary_10_1007_s00432_021_03627_1 crossref_primary_10_3390_biology12101337 crossref_primary_10_3390_cancers14051221 crossref_primary_10_1016_j_canlet_2022_215880 crossref_primary_10_3389_fimmu_2022_1043667 crossref_primary_10_3390_cancers12082123 crossref_primary_10_1155_2022_4237327 crossref_primary_10_1038_s41392_024_02030_9 crossref_primary_10_1124_dmd_124_001665 crossref_primary_10_2174_0115680266284527240118041129 crossref_primary_10_62347_NXMR6806 crossref_primary_10_1002_jcb_30252 crossref_primary_10_1186_s11658_023_00438_9 crossref_primary_10_3390_cancers15030931 crossref_primary_10_1016_j_stemcr_2023_11_013 crossref_primary_10_1186_s12906_023_03872_6 crossref_primary_10_18632_aging_205179 crossref_primary_10_1016_j_trsl_2023_05_005 |
| Cites_doi | 10.1038/onc.2011.656 10.1093/carcin/bgs214 10.1093/nar/27.11.2291 10.1007/s11095-011-0645-9 10.1634/stemcells.2006-0426 10.1073/pnas.91.2.822 10.1186/s13046-016-0478-9 10.1016/j.canlet.2013.07.030 10.1002/ijc.29033 10.1056/NEJMoa0708857 10.1016/j.canlet.2012.10.021 10.1038/onc.2014.334 10.1038/ng.127 10.1038/ng.3291 10.14218/JCTH.2015.00024 10.1038/nrg.2016.13 10.1016/j.cell.2005.02.018 10.1002/hep.25745 10.1158/1535-7163.MCT-10-0609 10.1158/1078-0432.CCR-13-3274 10.1182/blood-2005-08-007377 10.1158/1541-7786.MCR-09-0496 10.1038/ncomms8631 10.1016/j.cellsig.2017.01.017 10.1002/stem.2059 10.1016/j.it.2014.12.008 10.1016/S1470-2045(08)70285-7 10.1016/j.ejmech.2012.07.023 10.1016/S1386-6346(03)00091-3 10.1053/j.gastro.2014.08.039 10.3748/wjg.v20.i8.2098 10.1038/ajg.2015.100 10.1245/s10434-012-2314-6 10.1002/hep.24199 10.1053/j.gastro.2011.12.061 10.1016/j.cld.2015.01.001 10.1038/35102167 10.1016/S1470-2045(11)70066-3 10.1016/j.neo.2017.05.002 10.1007/s13402-017-0354-4 10.1038/s41374-018-0079-7 10.1177/1947601910388271 10.1002/hep.23692 10.1016/j.addr.2015.05.001 10.1098/rsos.181006 10.1097/01.cad.0000173476.67239.3b 10.3892/or.2017.5722 10.1158/1055-9965.EPI-15-0578 10.3748/wjg.v12.i16.2563 10.1093/carcin/bgt139 10.1016/S0002-9440(10)63495-5 10.1007/s10620-012-2136-1 10.1074/jbc.M309002200 10.1016/j.molcel.2012.01.015 10.1186/s12935-017-0398-6 10.3892/ol.2015.3077 10.1053/j.gastro.2007.01.034 10.1007/s13277-016-4941-1 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2019 BioMed Central Ltd. 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s). 2019 |
| Copyright_xml | – notice: COPYRIGHT 2019 BioMed Central Ltd. – notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s). 2019 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1186/s13046-019-1442-2 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1756-9966 |
| EndPage | 18 |
| ExternalDocumentID | oai_doaj_org_article_81ffe598b12d460aa2b79bcea12cd258 PMC6878666 A607403001 31771617 10_1186_s13046_019_1442_2 |
| Genre | Journal Article |
| GeographicLocations | Taiwan United States--US |
| GeographicLocations_xml | – name: Taiwan – name: United States--US |
| GrantInformation_xml | – fundername: Ministry of Science and Technology grantid: MOST 107-2321-B-038-002 – fundername: Ministry of Science and Technology (VN) grantid: MOST 106-3114-B-038-001 – fundername: Ministry of Education (KR) grantid: DP2-107-21121-01-T-02 – fundername: Ministry of Science and Technology (VN) grantid: MOST 105-2628-B-038-008-MY3 – fundername: Ministry of Science and Technology grantid: MOST108-2321-B-038-003 – fundername: Taipei Medical University (TW) grantid: TMU-T104-06 – fundername: Chiayi Chang Gung Memorial Hospital (TW) grantid: CORPG6F0053 – fundername: Ministry of Science and Technology grantid: MOST 107-2314-B-038-057 – fundername: Taipei Medical University (TW) grantid: 105TMU-CIT-01-3 – fundername: Taipei Medical University (TW) grantid: TMU-T105-06 – fundername: ; grantid: MOST 105-2628-B-038-008-MY3; MOST 106-3114-B-038-001 – fundername: ; grantid: MOST 107-2321-B-038-002; MOST 107-2314-B-038-057; MOST108-2321-B-038-003 – fundername: ; grantid: DP2-108-21121-01-T-02-02 – fundername: ; grantid: CORPG6F0053 – fundername: ; grantid: TMU-T106-03 – fundername: ; grantid: CMRPG6F0163 – fundername: ; grantid: DP2-107-21121-01-T-02 – fundername: ; grantid: TMU-T104-06; TMU-T105-06; 105TMU-CIT-01-3 |
| GroupedDBID | --- 0R~ 29K 2WC 4.4 5GY 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ADBBV ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 D-I DIK DU5 E3Z EBD EBLON EBS EJD ESX F5P FYUFA GROUPED_DOAJ H13 HMCUK HYE IAO IEA IHR IHW INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ TR2 TUS UKHRP ~8M CGR CUY CVF ECM EIF NPM PMFND 3V. 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQUKI 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c657t-d1f7036c0657886e2a081421d32e21ccdd40a50b56f6340b06607499905d37f83 |
| IEDL.DBID | DOA |
| ISSN | 1756-9966 0392-9078 |
| IngestDate | Wed Aug 27 01:20:26 EDT 2025 Thu Aug 21 14:35:54 EDT 2025 Fri Jul 11 06:30:07 EDT 2025 Fri Jul 25 22:51:40 EDT 2025 Tue Jun 17 20:53:04 EDT 2025 Tue Jun 10 20:24:49 EDT 2025 Thu May 22 21:05:39 EDT 2025 Thu Apr 03 07:08:15 EDT 2025 Tue Jul 01 02:26:38 EDT 2025 Thu Apr 24 23:00:53 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | OCT4 DNMT3b Phospho-STAT3 Hepatocellular carcinoma Drug resistance Interleukin-6 |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c657t-d1f7036c0657886e2a081421d32e21ccdd40a50b56f6340b06607499905d37f83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-6020-9998 |
| OpenAccessLink | https://doaj.org/article/81ffe598b12d460aa2b79bcea12cd258 |
| PMID | 31771617 |
| PQID | 2328365713 |
| PQPubID | 105475 |
| PageCount | 18 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_81ffe598b12d460aa2b79bcea12cd258 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6878666 proquest_miscellaneous_2319195410 proquest_journals_2328365713 gale_infotracmisc_A607403001 gale_infotracacademiconefile_A607403001 gale_healthsolutions_A607403001 pubmed_primary_31771617 crossref_primary_10_1186_s13046_019_1442_2 crossref_citationtrail_10_1186_s13046_019_1442_2 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-11-26 |
| PublicationDateYYYYMMDD | 2019-11-26 |
| PublicationDate_xml | – month: 11 year: 2019 text: 2019-11-26 day: 26 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Journal of experimental & clinical cancer research |
| PublicationTitleAlternate | J Exp Clin Cancer Res |
| PublicationYear | 2019 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | M Nagai (1442_CR33) 2003; 26 KA McGlynn (1442_CR3) 2015; 19 J Shan (1442_CR55) 2012; 56 Y Li (1442_CR44) 2012; 33 Y Babaie (1442_CR19) 2007; 25 M Soresi (1442_CR18) 2006; 12 DE Linn (1442_CR24) 2010; 1 SM Hammond (1442_CR57) 2015; 87 L Gao (1442_CR11) 2017; 36 JC Wang (1442_CR37) 2015; 9 S Lee (1442_CR35) 2003; 163 H Unsal (1442_CR56) 1994; 91 T Reya (1442_CR12) 2001; 414 M Scarola (1442_CR29) 2015; 6 J Liu (1442_CR63) 2017; 38 AP Feinberg (1442_CR27) 2016; 17 S Wan (1442_CR17) 2014; 147 D Zeineddine (1442_CR23) 2014; 3 L Gao (1442_CR10) 2018; 41 H van Malenstein (1442_CR40) 2013; 329 J Mauer (1442_CR15) 2015; 36 Z Yu (1442_CR58) 2012; 3 E Foran (1442_CR49) 2010; 8 TS Chang (1442_CR14) 2015; 21 H Lopez-Bertoni (1442_CR30) 2015; 34 Y Jia (1442_CR60) 2012; 27 WC Chen (1442_CR42) 2014; 9 NN Siddiqui (1442_CR38) 2016; 37 HB El-Serag (1442_CR2) 2012; 142 D Morgensztern (1442_CR8) 2005; 16 DS Chandrashekar (1442_CR46) 2017; 19 S Murakami (1442_CR26) 2015; 33 B Xie (1442_CR61) 2012; 57 L Wang (1442_CR22) 2013; 34 IY Park (1442_CR36) 2007; 132 X Guo (1442_CR59) 2017; 17 W Miller (1442_CR62) 2011; 12 Q Zhang (1442_CR41) 2006; 108 T Lan (1442_CR39) 2015; 3 LA Torre (1442_CR1) 2016; 25 JM Llovet (1442_CR6) 2008; 359 I Ben-Porath (1442_CR20) 2008; 40 M Rokavec (1442_CR16) 2012; 45 KF Chen (1442_CR9) 2012; 55 A Balakrishnan (1442_CR51) 2018; 98 Z Guo (1442_CR13) 2014; 20 N Hattori (1442_CR21) 2004; 279 CC Liu (1442_CR48) 2015; 136 X Yin (1442_CR53) 2012; 19 BK Oh (1442_CR34) 2007; 20 M Kulis (1442_CR31) 2015; 47 C Braconi (1442_CR43) 2010; 51 XQ Wang (1442_CR52) 2010; 52 SM Kumar (1442_CR25) 2012; 31 D Kuck (1442_CR47) 2010; 9 SA Read (1442_CR54) 2014; 345 O Menyhart (1442_CR45) 2018; 5 K Hochedlinger (1442_CR28) 2005; 121 J Bruix (1442_CR5) 2011; 53 AL Cheng (1442_CR7) 2009; 10 L Nagaprashantha (1442_CR64) 2012; 29 Z Quan (1442_CR50) 2017; 32 TS Chang (1442_CR4) 2015; 110 KD Robertson (1442_CR32) 1999; 27 31931847 - J Exp Clin Cancer Res. 2020 Jan 13;39(1):10 |
| References_xml | – volume: 31 start-page: 4898 year: 2012 ident: 1442_CR25 publication-title: Oncogene. doi: 10.1038/onc.2011.656 – volume: 33 start-page: 1889 year: 2012 ident: 1442_CR44 publication-title: Carcinogenesis. doi: 10.1093/carcin/bgs214 – volume: 27 start-page: 2291 year: 1999 ident: 1442_CR32 publication-title: Nucleic Acids Res doi: 10.1093/nar/27.11.2291 – volume: 29 start-page: 621 year: 2012 ident: 1442_CR64 publication-title: Pharm Res doi: 10.1007/s11095-011-0645-9 – volume: 25 start-page: 500 year: 2007 ident: 1442_CR19 publication-title: Stem Cells doi: 10.1634/stemcells.2006-0426 – volume: 91 start-page: 822 year: 1994 ident: 1442_CR56 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.91.2.822 – volume: 36 start-page: 8 year: 2017 ident: 1442_CR11 publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-016-0478-9 – volume: 345 start-page: 174 year: 2014 ident: 1442_CR54 publication-title: Cancer Lett doi: 10.1016/j.canlet.2013.07.030 – volume: 136 start-page: 547 year: 2015 ident: 1442_CR48 publication-title: Int J Cancer doi: 10.1002/ijc.29033 – volume: 359 start-page: 378 year: 2008 ident: 1442_CR6 publication-title: N Engl J Med doi: 10.1056/NEJMoa0708857 – volume: 329 start-page: 74 year: 2013 ident: 1442_CR40 publication-title: Cancer Lett doi: 10.1016/j.canlet.2012.10.021 – volume: 3 start-page: 74 year: 2014 ident: 1442_CR23 publication-title: Am J Stem Cells – volume: 34 start-page: 3994 year: 2015 ident: 1442_CR30 publication-title: Oncogene. doi: 10.1038/onc.2014.334 – volume: 9 year: 2014 ident: 1442_CR42 publication-title: PLoS One – volume: 51 start-page: 881 year: 2010 ident: 1442_CR43 publication-title: Hepatology. – volume: 40 start-page: 499 year: 2008 ident: 1442_CR20 publication-title: Nat Genet doi: 10.1038/ng.127 – volume: 47 start-page: 746 year: 2015 ident: 1442_CR31 publication-title: Nat Genet doi: 10.1038/ng.3291 – volume: 3 start-page: 271 year: 2015 ident: 1442_CR39 publication-title: J Clin Transl Hepatol doi: 10.14218/JCTH.2015.00024 – volume: 17 start-page: 284 year: 2016 ident: 1442_CR27 publication-title: Nat Rev Genet doi: 10.1038/nrg.2016.13 – volume: 121 start-page: 465 year: 2005 ident: 1442_CR28 publication-title: Cell. doi: 10.1016/j.cell.2005.02.018 – volume: 56 start-page: 1004 year: 2012 ident: 1442_CR55 publication-title: Hepatology. doi: 10.1002/hep.25745 – volume: 9 start-page: 3015 year: 2010 ident: 1442_CR47 publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-10-0609 – volume: 21 start-page: 201 year: 2015 ident: 1442_CR14 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-3274 – volume: 108 start-page: 1058 year: 2006 ident: 1442_CR41 publication-title: Blood doi: 10.1182/blood-2005-08-007377 – volume: 8 start-page: 471 year: 2010 ident: 1442_CR49 publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-09-0496 – volume: 6 start-page: 7631 year: 2015 ident: 1442_CR29 publication-title: Nat Commun doi: 10.1038/ncomms8631 – volume: 32 start-page: 48 year: 2017 ident: 1442_CR50 publication-title: Cell Signal doi: 10.1016/j.cellsig.2017.01.017 – volume: 33 start-page: 2652 year: 2015 ident: 1442_CR26 publication-title: Stem Cells doi: 10.1002/stem.2059 – volume: 36 start-page: 92 year: 2015 ident: 1442_CR15 publication-title: Trends Immunol doi: 10.1016/j.it.2014.12.008 – volume: 10 start-page: 25 year: 2009 ident: 1442_CR7 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(08)70285-7 – volume: 55 start-page: 220 year: 2012 ident: 1442_CR9 publication-title: Eur J Med Chem doi: 10.1016/j.ejmech.2012.07.023 – volume: 20 start-page: 65 year: 2007 ident: 1442_CR34 publication-title: Int J Mol Med – volume: 26 start-page: 186 year: 2003 ident: 1442_CR33 publication-title: Hepatol Res doi: 10.1016/S1386-6346(03)00091-3 – volume: 147 start-page: 1393 year: 2014 ident: 1442_CR17 publication-title: Gastroenterology. doi: 10.1053/j.gastro.2014.08.039 – volume: 20 start-page: 2098 year: 2014 ident: 1442_CR13 publication-title: World J Gastroenterol doi: 10.3748/wjg.v20.i8.2098 – volume: 110 start-page: 836 year: 2015 ident: 1442_CR4 publication-title: Am J Gastroenterol doi: 10.1038/ajg.2015.100 – volume: 19 start-page: 2877 year: 2012 ident: 1442_CR53 publication-title: Ann Surg Oncol doi: 10.1245/s10434-012-2314-6 – volume: 3 start-page: 191 year: 2012 ident: 1442_CR58 publication-title: Front Genet – volume: 53 start-page: 1020 year: 2011 ident: 1442_CR5 publication-title: Hepatology. doi: 10.1002/hep.24199 – volume: 142 start-page: 1264 year: 2012 ident: 1442_CR2 publication-title: Gastroenterology doi: 10.1053/j.gastro.2011.12.061 – volume: 19 start-page: 223 year: 2015 ident: 1442_CR3 publication-title: Clin Liver Dis doi: 10.1016/j.cld.2015.01.001 – volume: 414 start-page: 105 year: 2001 ident: 1442_CR12 publication-title: Nature. doi: 10.1038/35102167 – volume: 12 start-page: 326 year: 2011 ident: 1442_CR62 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(11)70066-3 – volume: 19 start-page: 649 year: 2017 ident: 1442_CR46 publication-title: Neoplasia. doi: 10.1016/j.neo.2017.05.002 – volume: 41 start-page: 85 year: 2018 ident: 1442_CR10 publication-title: Cell Oncol (Dordr) doi: 10.1007/s13402-017-0354-4 – volume: 98 start-page: 1143 year: 2018 ident: 1442_CR51 publication-title: Lab Investig doi: 10.1038/s41374-018-0079-7 – volume: 1 start-page: 908 year: 2010 ident: 1442_CR24 publication-title: Genes Cancer doi: 10.1177/1947601910388271 – volume: 52 start-page: 528 year: 2010 ident: 1442_CR52 publication-title: Hepatology. doi: 10.1002/hep.23692 – volume: 87 start-page: 3 year: 2015 ident: 1442_CR57 publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2015.05.001 – volume: 5 start-page: 181006 year: 2018 ident: 1442_CR45 publication-title: R Soc Open Sci doi: 10.1098/rsos.181006 – volume: 16 start-page: 797 year: 2005 ident: 1442_CR8 publication-title: Anti-Cancer Drugs doi: 10.1097/01.cad.0000173476.67239.3b – volume: 27 start-page: 1865 year: 2012 ident: 1442_CR60 publication-title: Oncol Rep – volume: 38 start-page: 899 year: 2017 ident: 1442_CR63 publication-title: Oncol Rep doi: 10.3892/or.2017.5722 – volume: 25 start-page: 16 year: 2016 ident: 1442_CR1 publication-title: Cancer Epidemiol Biomark Prev doi: 10.1158/1055-9965.EPI-15-0578 – volume: 12 start-page: 2563 year: 2006 ident: 1442_CR18 publication-title: World J Gastroenterol doi: 10.3748/wjg.v12.i16.2563 – volume: 34 start-page: 1773 year: 2013 ident: 1442_CR22 publication-title: Carcinogenesis. doi: 10.1093/carcin/bgt139 – volume: 163 start-page: 1371 year: 2003 ident: 1442_CR35 publication-title: Am J Pathol doi: 10.1016/S0002-9440(10)63495-5 – volume: 57 start-page: 1122 year: 2012 ident: 1442_CR61 publication-title: Dig Dis Sci doi: 10.1007/s10620-012-2136-1 – volume: 279 start-page: 17063 year: 2004 ident: 1442_CR21 publication-title: J Biol Chem doi: 10.1074/jbc.M309002200 – volume: 45 start-page: 777 year: 2012 ident: 1442_CR16 publication-title: Mol Cell doi: 10.1016/j.molcel.2012.01.015 – volume: 17 start-page: 29 year: 2017 ident: 1442_CR59 publication-title: Cancer Cell Int doi: 10.1186/s12935-017-0398-6 – volume: 9 start-page: 2499 year: 2015 ident: 1442_CR37 publication-title: Oncol Lett doi: 10.3892/ol.2015.3077 – volume: 132 start-page: 1476 year: 2007 ident: 1442_CR36 publication-title: Gastroenterology. doi: 10.1053/j.gastro.2007.01.034 – volume: 37 start-page: 10487 year: 2016 ident: 1442_CR38 publication-title: Tumour Biol doi: 10.1007/s13277-016-4941-1 – reference: 31931847 - J Exp Clin Cancer Res. 2020 Jan 13;39(1):10 |
| SSID | ssj0061919 |
| Score | 2.52395 |
| Snippet | The inflammatory cytokine interleukin-6 (IL-6) is critical for the expression of octamer-binding transcription factor 4 (OCT4), which is highly associated with... Background The inflammatory cytokine interleukin-6 (IL-6) is critical for the expression of octamer-binding transcription factor 4 (OCT4), which is highly... Abstract Background The inflammatory cytokine interleukin-6 (IL-6) is critical for the expression of octamer-binding transcription factor 4 (OCT4), which is... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 474 |
| SubjectTerms | Analysis Animal experimentation Animals Antineoplastic agents Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Cancer Carcinoma Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - genetics Carcinoma, Hepatocellular - metabolism Cell Line, Tumor Cytokines Disease Models, Animal DNA DNA (Cytosine-5-)-Methyltransferases - antagonists & inhibitors DNA (Cytosine-5-)-Methyltransferases - biosynthesis DNA (Cytosine-5-)-Methyltransferases - genetics DNA (Cytosine-5-)-Methyltransferases - metabolism DNA methylation DNA Methyltransferase 3B DNMT3b Drug resistance Drug Resistance, Neoplasm Enzyme-linked immunosorbent assay Female Health aspects Hep G2 Cells Hepatocellular carcinoma Heterografts Humans Inhibitor drugs Interleukin-6 Interleukin-6 - blood Interleukin-6 - genetics Interleukin-6 - metabolism Interleukins Kinases Liver cancer Liver Neoplasms - drug therapy Liver Neoplasms - genetics Liver Neoplasms - metabolism Medical research Methyltransferases Mice Mice, Inbred BALB C Mice, Inbred NOD Mice, Nude Mice, SCID Middle Aged OCT4 Octamer Transcription Factor-3 - biosynthesis Octamer Transcription Factor-3 - genetics Phospho-STAT3 Plasmids Prognosis Recurrence (Disease) RNA RNA interference Silence Sorafenib Sorafenib - pharmacology STAT3 Transcription Factor - metabolism Stem cells Targeted cancer therapy Transferases Tumors |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96gvgiftvz1AiCIIRt0jZJn2Q9PU5xzwf3YN9Cmo-7A233dvfAR_90Z7rZekW412ZS2pnJzG-SyQwhb20to41BMqnqhpW1tkyH2rNK1t75aMvc44nu7EQen5ZfF9UibbitU1rlzib2htp3DvfIJ-D5dSEriKk-LC8Zdo3C09XUQuM2uYOlyzClSy2GgAtig76xB3hIyRDXp1NNruVkzfFIEALpmkFIIZgY-aW-fP__RvqalxpnUF5zSUcPyP2EJel0K_yH5FZoH5G7s3Ra_pj8-XQymxfN5PvhvKThd0p5banrb_mt6RrEH0N70VAYQRwJCkBt6-my61YUM7faDp7TLtJz8FqbDnf5MW2VOuxA1Ha_LE19fuiXb0xOfsyn8wJedpZ6gj0hp0ef54fHLHVcYA5Yu2GeRyzI5QCXQGgsg7CAGErBfSGC4M55X-a2yptKRlmUeQN4BSAIYMy88oWKunhK9tquDc8JjUo6WwKHVM3LWKnaFjZEpYoQJeAEn5F8x2_jUjly7Irx0_RhiZZmKyIDIjIoIiMy8n6YstzW4riJ-CMKcSDEMtr9g251ZtKqNJrHGKpaN1z4UubWigZU1gXLhfOi0hl5jSpgtndSB2NgpvjbYB5znpF3PQWaA_h8Z9OtBmACFtYaUR6MKGEZu_HwTs1MMiNr80_pM_JmGMaZmBrXhu4KaVDNq5LnGXm21crhpwEcKgxgM6JG-jriynikvTjvi4xLrTSEtvs3f9YLck_0a4gzIQ_I3mZ1FV4CSts0r_ql-BfLTjis priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEA-lgvgifrtaNYIgCGs32WySfRA5q6WKVx-8g76FbD7aQt2td1eob_7pzuzlli4Wn3zdTI7b-cj8ZmcyQ8grW8toY5C5VHWTi1rbXIfa55WsvfPRisJjRnd6KA_m4stRdbRFNuOtEgOX14Z2OE9qvjh7e_nz13sw-He9wWu5u2SY3oOguM4hPOA5nMg3wDEptNOpGJIKECqwOiU2r902ck19B_-_z-krjmpcRHnFK-3fIbcTnKSTtfzvkq3Q3iM3pylhfp_8_ng4nZXN7re9maDhMlW9ttT1F_2WdAkaEEN72lBYQSgJOkBt6-l51y0oFm-1HTynXaQn4LhWHX7ox8pV6nAIUdv9sDSN-qGfv-Zy9_tsMivhx47TWLAHZL7_abZ3kKehC7mTlVrlnkXsyeUAmkB0LAO3ABoEZ77kgTPnvBeFrYqmklGWomgAsgAKAZhZVL5UUZcPyXbbteExoVFJZwVwSNVMxErVtrQhKlWGKAEq-IwUG34blzqS42CMM9NHJlqatYgMiMigiAzPyJthy_m6Hce_iD-gEAdC7KTdP-gWxyYZptEsxlDVumHcC1lYyxvQWhcs487zSmfkBaqAWV9LHc4DM8HXhhOyYBl53VOgjsLfdzZdbAAmYG-tEeXOiBIs2Y2XN2pmNoZgAPHqEmTByoy8HJZxJ1bHtaG7QBpU7UqwIiOP1lo5vDTgQ4UxbEbUSF9HXBmvtKcnfZ9xqZWG6PbJ_2DjU3KL95bGci53yPZqcRGeAZxbNc97I_0DxTJHGg priority: 102 providerName: Scholars Portal |
| Title | DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31771617 https://www.proquest.com/docview/2328365713 https://www.proquest.com/docview/2319195410 https://pubmed.ncbi.nlm.nih.gov/PMC6878666 https://doaj.org/article/81ffe598b12d460aa2b79bcea12cd258 |
| Volume | 38 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA96gvgiftvzXCMIghC2SdMkfdw97zjFXeXcg8WXkObDO_Da43YPfPRPd9Jmly2CvvjSh2ZamvnI_KaZzCD0xlQimOAFEbKqCa-UIcpXjpSictYFw3MXd3Rnc3Fyxj8uy-VOq6-YE9aXB-4ZN1Y0BF9WqqbMcZEbw2p4q_WGMutY2R3zBZ-3Cab6NRiiAlqlPUyqxHhF4wYghM0VgQCCETbwQl2x_j-X5B2fNMyX3HFAxw_Q_YQc8aT_4ofolm8eobuztDf-GP16P58tinr8-XDBsf-ZElwbbLszfSu8AmEH31zUGEYiagRxY9M4fNW21zjmaTUt3MdtwOfgo9Zt_Kcfk1Sxjf2GmvbS4NTVB3_4RMT462KyKOBl31MHsCfo7PhocXhCUn8FYkUp18TREMtvWUAhEAgLzwzgA86oK5hn1FrneG7KvC5FEAXPa0AnADgAUealK2RQxVO017SNf45wkMIaDhySFeWhlJUpjA9SFj4IQAUuQ_mG39qm4uOxB8YP3QUhSuheRBpEpKOINMvQu-0jV33ljb8RT6MQt4SxaHZ3A1RJJ1XS_1KlDL2KKqD7E6hb09eTOG1YDHOaobcdRTR--Hxr0hkGYEIsozWgPBhQgtHa4fBGzXRaNFYawK0qQBa0yNDr7XB8MibCNb69iTRRtUtO8ww967VyO2mAgjKGqxmSA30dcGU40lycdyXFhZIKAtn9_8HGF-ge6yyNEiYO0N76-sa_BOS2rkfotlzKEbozPZp_OR11JgvXGVdwPZ1--w23oER4 |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdGJwEviG8CgxkJhIRkNXESJ3lAqPtSy9qCoJP25jn-2CZBUtpOwBt_EX8jd_koi5D2ttf4bCW-8_3ucuc7Ql6pTDjlrGAiyXIWZaliqc0Mi0VmtHEq8g1GdCdTMTyKPhzHxxvkT3sXBtMqW51YKWpTavxH3gfkT0MRg0_1fv6dYdcojK62LTRqsTi0v36Ay7Z8N9oD_r7m_GB_tjtkTVcBpmH6ipnAYdEpDdgL7p-wXAEqRjwwIbc80NqYyFexn8fCiTDyc8BkgFmwo_zYhIlLQ1j3BtmMQnBlemRzZ3_66XOr-8EbqVqJACYLhp5EE0cNUtFfBhiEBNc9Y-DEcMY7SFg1DPgfFi7hYjdn8xIIHtwldxrrlQ5qcbtHNmxxn9ycNPH5B-T33nQyC_P-x91ZRO3PJsm2oLq6V7ikSxA4Z4vznMIIWq4gclQVhs7LckExV6wo4TktHT0DnFyVGFfARFmqsedRUX5TtOksREdjJvpfZoNZCIudNl3IHpKja-HGI9IrysI-IdQlQqsIdijJgsjFSaZCZV2ShNYJsEyMR_x2v6VuCqBjH46vsnKEUiFrFklgkUQWSe6Rt-sp87r6x1XEO8jENSEW7q4elItT2egBmQbO2ThL84CbSPhK8RwOibYq4NrwOPXINoqArG_BrtWPHOBng0L2A4-8qShQAcHra9Xco4BNwFJeHcqtDiUoDt0dbsVMNoprKf8dM4-8XA_jTEzGK2x5gTQo5nEU-B55XEvl-qPBHE3QZfZI0pHXzq50R4rzs6qsuUiTFJzpp1e_1ja5NZxNxnI8mh4-I7d5dZ4CxsUW6a0WF_Y52Iir_EVzMCk5uW5d8BcCu3QL |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=DNMT3b%2FOCT4+expression+confers+sorafenib+resistance+and+poor+prognosis+of+hepatocellular+carcinoma+through+IL-6%2FSTAT3+regulation&rft.jtitle=Journal+of+experimental+%26+clinical+cancer+research&rft.au=Ssu-Chuan+Lai&rft.au=Yu-Ting+Su&rft.au=Ching-Chi+Chi&rft.au=Yung-Che+Kuo&rft.date=2019-11-26&rft.pub=BMC&rft.eissn=1756-9966&rft.volume=38&rft.issue=1&rft.spage=1&rft.epage=18&rft_id=info:doi/10.1186%2Fs13046-019-1442-2&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_81ffe598b12d460aa2b79bcea12cd258 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-9966&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-9966&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-9966&client=summon |